Monday, October 27, 2025

Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics

For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh of Revive Therapeutics (CSE: RVV), and founder of Psilocin Pharma Corp, a subsidiary of the company. Derek joins us to discuss his outlook on that of the psychedelics market as a whole, and discuss what Revive is working on from a psychedelics standpoint.

Psilocin Pharma, which was acquired by Revive Therapeutics earlier this year, is the psychedelic-focused arm of the company. The company has developed production solutions for the active compound psilocybin. The firm has developed six formulations to date, while owning a robust pipeline of ongoing research and development work within the psychedelics space.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Goliath Resources Drills 10.72 g/t Gold Over 7.83 Metres At Surebet

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Related News

Revive Receives Approval From Independent Review Board For Phase Three Study

Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials...

Monday, August 31, 2020, 08:56:26 AM

Revive Therapeutics Closes $23.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally...

Friday, February 12, 2021, 11:38:53 AM

Roadman Investments To Establish Psychedelic Conference for Investors

Roadman Investments (TSXV: LITT), a firm focused on the production of mushrooms, announced this morning...

Thursday, September 5, 2019, 08:42:39 AM

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the...

Monday, June 28, 2021, 07:37:00 AM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM